AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31673875 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg/day orally on days 1-11, single oral dose of erdafitinib 4 mg on day 5
Number of subjects: 0
Study 31673875 — intervention group
Group type: COMPARATOR
Intervention: Single oral dose of erdafitinib 4 mg
Number of subjects: 0
Study 31673875 — intervention group
Group type: COMPARATOR
Intervention: Coadministration of erdafitinib with itraconazole
Number of subjects: 0
Study 31673875 — intervention group
Group type: COMPARATOR
Intervention: Coadministration of erdafitinib with fluconazole or itraconazole
Number of subjects: 0
Study 29293386 — intervention group
Group type: COMPARATOR
Intervention: Intensity-Modulated Radiotherapy (IMRT)
Number of subjects: 149
Study 29293386 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Scattering Proton Therapy (PSPT)
Number of subjects: 149
Study 27437826 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-1005 (MIV-150 and zinc acetate in a carrageenan gel)
Number of subjects: 20
Study 27437826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23982436 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care (NLC)
Number of subjects: 181
Study 22418831 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg daily for 5 days)
Number of subjects: 15
Study 22418831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 22418831 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 15
Study 21112423 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise (AE)
Number of subjects: 64
Study 21112423 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise (CE)
Number of subjects: 64
Study 21112423 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 64
Study 18178780 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet-based regimen
Number of subjects: 552
Study 18178780 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 552
Study 15968009 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - 0.625 mg of conjugated estrogen daily, plus 5 mg of medroxyprogesterone for 12 days per month
Number of subjects: 351
Study 15968009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 14529932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg daily)
Number of subjects: 64
Study 14529932 — intervention group
Group type: COMPARATOR
Intervention: Control (no ketoconazole)
Number of subjects: 64
Study 11127126 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnification (3x to 7.5x) with adequate contrast reserve
Number of subjects: 0
Study 11127126 — intervention group
Group type: EXPERIMENTAL
Intervention: Low contrast reserve
Number of subjects: 0
Study 11127126 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnification higher than required for letter recognition (increased acuity reserve)
Number of subjects: 0
Study 11127126 — intervention group
Group type: EXPERIMENTAL
Intervention: High contrast reserve with magnifications of 5x and higher
Number of subjects: 0
Study 9336154 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 290
Study 1283553 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain experience as measured by the McGill Pain Questionnaire
Number of subjects: 246
Study 1283553 — intervention group
Group type: EXPERIMENTAL
Intervention: Deeper somatic pain descriptors (e.g., throbbing, stabbing, cramping, pulling, burning)
Number of subjects: 246
Study 1283553 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial pain descriptors (e.g., pricking, sharp, pinching, itching, sore, tender)
Number of subjects: 246
Study 1283553 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of findings with Taenzer's study in Canada
Number of subjects: 246
Study 2864048 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofentanil 5 micrograms
Number of subjects: 60
Study 2864048 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.3 mg
Number of subjects: 60
Study 2864048 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 60
Study 28375777 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT) for 24 weeks
Number of subjects: 32
Study 26296097 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly engaging conditions (game group)
Number of subjects: 40
Study 26296097 — intervention group
Group type: COMPARATOR
Intervention: Mechanically identical but less engaging conditions (sterile group)
Number of subjects: 40
Study 24117531 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat meal
Number of subjects: 29
Study 24117531 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 29
Study 24117531 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg (single dose)
Number of subjects: 29
Study 24117531 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg (multiple doses)
Number of subjects: 29
Study 22332528 — intervention group
Group type: EXPERIMENTAL
Intervention: Acutrak full thread headless hollow compression screw (surgical group)
Number of subjects: 31
Study 22332528 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (control group)
Number of subjects: 31
Study 19738394 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscocanalostomy
Number of subjects: 17
Study 19738394 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sclerectomy
Number of subjects: 17
Study 19738394 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sclerectomy plus mitomycin C (MMC)
Number of subjects: 17
Study 19738394 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 17
Study 19738394 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy plus MMC
Number of subjects: 17
Study 19738394 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscocanalostomy and Deep Sclerectomy
Number of subjects: 17
Study 17509338 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 60
Study 17509338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15958837 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir/Ritonavir 800/200 mg twice daily
Number of subjects: 44
Study 15958837 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir/Ritonavir 400/400 mg twice daily
Number of subjects: 44
Study 11796432 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation (TSI) 300 mg
Number of subjects: 128
Study 11796432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 10232690 — intervention group
Group type: EXPERIMENTAL
Intervention: big ET‐1 infusion (0.2, 1, and 4 pmol/kg per min for 20 min)
Number of subjects: 53
Study 10232690 — intervention group
Group type: EXPERIMENTAL
Intervention: big ET‐1 infusion
Number of subjects: 53
Study 10232690 — intervention group
Group type: EXPERIMENTAL
Intervention: ET‐1 infusion
Number of subjects: 53
Study 10232690 — intervention group
Group type: COMPARATOR
Intervention: HD procedure
Number of subjects: 53
Study 10232690 — intervention group
Group type: COMPARATOR
Intervention: HD patients with ischemic heart disease
Number of subjects: 53
Study 8907097 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-contact weight loss group (videotaped)
Number of subjects: 71
Study 8907097 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-contact weight loss group (not videotaped)
Number of subjects: 71
Study 8907097 — intervention group
Group type: EXPERIMENTAL
Intervention: Television-delivered group (observed videotaped sessions)
Number of subjects: 71
Study 8907097 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 71
Study 8907097 — intervention group
Group type: EXPERIMENTAL
Intervention: Television-delivered group
Number of subjects: 71
Study 8907097 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-contact group
Number of subjects: 71
Study 8907097 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped group
Number of subjects: 71
Study 1297921 — intervention group
Group type: EXPERIMENTAL
Intervention: Wallaby Phototherapy System (24 hours of light exposure)
Number of subjects: 46
Study 1297921 — intervention group
Group type: COMPARATOR
Intervention: Control group (any treatment for hyperbilirubinemia)
Number of subjects: 46
Study 1297921 — intervention group
Group type: EXPERIMENTAL
Intervention: Wallaby Phototherapy System
Number of subjects: 46
Study 1297921 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 6382639 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0
Study 6382639 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 0
Study 31657794 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIE)
Number of subjects: 47
Study 31657794 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Exercise (SIE)
Number of subjects: 47
Study 31657794 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated Sprint Exercise (RSE)
Number of subjects: 47
Study 31657794 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Exercise (MCE)
Number of subjects: 47
Study 29389245 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g daily ARA for 4 weeks
Number of subjects: 19
Study 26540652 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 70
Study 26540652 — intervention group
Group type: COMPARATOR
Intervention: Standard conservative therapy
Number of subjects: 70
Study 23583250 — intervention group
Group type: EXPERIMENTAL
Intervention: hs‐TnI assay with TIMI risk score = 0
Number of subjects: 2544
Study 23583250 — intervention group
Group type: EXPERIMENTAL
Intervention: hs‐TnI assay with TIMI risk score ≤ 1
Number of subjects: 2544
Study 23583250 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI risk score = 0 in the primary cohort
Number of subjects: 2544
Study 23583250 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI risk score ≤ 1 in the primary cohort
Number of subjects: 2544
Study 23583250 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI risk score ≤ 1 in the secondary cohort
Number of subjects: 2544
Study 21650060 — intervention group
Group type: EXPERIMENTAL
Intervention: Uvulopalatopharyngoplasty with partial resection of the musculus uvulae and preservation of uvulae mucosa
Number of subjects: 36
Study 21650060 — intervention group
Group type: COMPARATOR
Intervention: Uvulopalatopharyngoplasty with uvulae preservation
Number of subjects: 36
Study 19704275 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace therapy for compression fractures
Number of subjects: 133
Study 19704275 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy and postural instructions for compression fractures
Number of subjects: 133
Study 19704275 — intervention group
Group type: COMPARATOR
Intervention: Brace or Plaster of Paris cast for burst fractures
Number of subjects: 133
Study 19704275 — intervention group
Group type: COMPARATOR
Intervention: Plaster of Paris cast for burst fractures
Number of subjects: 133
Study 16926249 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant (doses 10-60 mg)
Number of subjects: 20
Study 16926249 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant
Number of subjects: 20
Study 16926249 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 15019652 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs with 'soft' endpoints using surrogate outcomes (72, 61%)
Number of subjects: 119
Study 15019652 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs with numerical outcomes (102, 86%)
Number of subjects: 119
Study 15019652 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs with deficiencies in trial quality (12 or more dimensions deficient in half of the studies)
Number of subjects: 119
Study 15019652 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs lacking blinding and variations in surgical technique
Number of subjects: 119
Study 15019652 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative analysis of large case series and databases
Number of subjects: 119
Study 11385196 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol group (mothers chewed xylitol-sweetened gum for 21 months starting 3 months after delivery)
Number of subjects: 195
Study 11385196 — intervention group
Group type: COMPARATOR
Intervention: Fluoride group (mothers received fluoride varnish treatments at 6, 12, and 18 months after delivery)
Number of subjects: 195
Study 11385196 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine group (mothers received chlorhexidine varnish treatments at 6, 12, and 18 months after delivery)
Number of subjects: 195
Study 9434916 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory Pressure Support (IPS)
Number of subjects: 10
Study 9434916 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Automatic Tube Compensation (ATC-in)
Number of subjects: 10
Study 9434916 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory and Expiratory Automatic Tube Compensation (ATC-in-ex)
Number of subjects: 10
Study 9434916 — intervention group
Group type: COMPARATOR
Intervention: IPS
Number of subjects: 10
Study 9434916 — intervention group
Group type: EXPERIMENTAL
Intervention: ATC
Number of subjects: 10
Study 8506477 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (400 mg twice daily for 10 days)
Number of subjects: 268
Study 8506477 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (2 g intramuscularly) followed by doxycycline (100 mg twice daily orally for 10 days)
Number of subjects: 268
Study 3693872 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinpocetine 40 mg
Number of subjects: 8
Study 3693872 — intervention group
Group type: COMPARATOR
Intervention: Flunitrazepam
Number of subjects: 8
Study 29956396 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology delivered by caregivers
Number of subjects: 256
Study 29956396 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 256
Study 27523947 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidacloprid 10% and moxidectin 2.5% spot on (G1)
Number of subjects: 47
Study 27523947 — intervention group
Group type: EXPERIMENTAL
Intervention: Milbemycin oxime/praziquantel tablets (G3)
Number of subjects: 47
Study 27523947 — intervention group
Group type: COMPARATOR
Intervention: Untreated control (G2)
Number of subjects: 47
Study 24871654 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Ginseol K‐g1 (300 mg)
Number of subjects: 90
Study 24871654 — intervention group
Group type: COMPARATOR
Intervention: Low-dose Ginseol K‐g1 (100 mg)
Number of subjects: 90
Study 24871654 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 90
Study 22545932 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation training of nurses (3-day residential training course on Stages of Change model, Motivational Interviewing, and guidelines for cardiovascular prevention)
Number of subjects: 212
Study 22545932 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation training of nurses
Number of subjects: 212
Study 21186645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloferon liniment in combined therapy
Number of subjects: 40
Study 18444867 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line ART regimens including zidovudine-lamivudine plus tenofovir disoproxil fumarate (74% of patients), nevirapine (16%), and abacavir (9%)
Number of subjects: 3316
Study 18444867 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line ART regimens
Number of subjects: 3316
Study 18794178 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg twice weekly)
Number of subjects: 254
Study 18794178 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept plus sulfasalazine (2-3 g/day)
Number of subjects: 254
Study 18794178 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine
Number of subjects: 254
Study 15786440 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol via MDI-spacer (2 puffs, 100 microg/puff)
Number of subjects: 47
Study 15786440 — intervention group
Group type: COMPARATOR
Intervention: Jet nebulizer (0.15 mg/kg salbutamol respiratory solution)
Number of subjects: 47
Study 11976156 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber diet (4 servings/d of foods containing beta-glucan or psyllium delivering 8 g/d more soluble fiber)
Number of subjects: 68
Study 11976156 — intervention group
Group type: COMPARATOR
Intervention: Control diet (low-fat, low-cholesterol)
Number of subjects: 68
Study 9758392 — intervention group
Group type: EXPERIMENTAL
Intervention: Language task
Number of subjects: 11
Study 9758392 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-recognition task
Number of subjects: 11
Study 8111572 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized Intermittent Mandatory Ventilation (SIMV)
Number of subjects: 21
Study 8111572 — intervention group
Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 21
Study 3261614 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic oxytocin and ergotamine intramuscularly (10 women)
Number of subjects: 25
Study 3261614 — intervention group
Group type: COMPARATOR
Intervention: No treatment (15 women)
Number of subjects: 25
Study 11318787 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (A) 250 mg, orally, administered at -210 minutes and -60 minutes
Number of subjects: 6
Study 11318787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 11318787 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (100 microg, iv, 0 minutes)
Number of subjects: 6
Study 11318787 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH plus Acipimox (A)
Number of subjects: 6
Study 30107471 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocity prime
Number of subjects: 420
Study 30107471 — intervention group
Group type: COMPARATOR
Intervention: Control message
Number of subjects: 420
Study 30412513 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation for 4 weeks
Number of subjects: 30
Study 30412513 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 27379793 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (8 g kg(‐1))
Number of subjects: 12
Study 27379793 — intervention group
Group type: COMPARATOR
Intervention: Low carbohydrate diet (3 g kg(‐1))
Number of subjects: 12
Study 24287674 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PVP) and kyphoplasty (PKP)
Number of subjects: 290
Study 24287674 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 290
Study 22299124 — intervention group
Group type: EXPERIMENTAL
Intervention: NitrAdine
Number of subjects: 92
Study 22299124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 19713256 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX 0.5 microg/kg
Number of subjects: 326
Study 19713256 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX 1 microg/kg
Number of subjects: 326
Study 19713256 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX (both doses)
Number of subjects: 326
Study 18631245 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg azithromycin once a day for 3 days
Number of subjects: 24
Study 18631245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15921833 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical torque during slow arm-raising movements
Number of subjects: 20
Study 15921833 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical torque during rapid arm-raising movements
Number of subjects: 20
Study 12022709 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg o.d.
Number of subjects: 983
Study 12022709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 983
Study 10029593 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (LDMTX)
Number of subjects: 121
Study 10029593 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX)
Number of subjects: 121
Study 9454116 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystallization test with cupric chloride solution in patients with head and neck neoplasms
Number of subjects: 31
Study 9454116 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 31
Study 2181603 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 3335
Study 2181603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3335
Study 343256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin and cephalexin (prophylactic antibiotics)
Number of subjects: 0
Study 31050026 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle intervention (interactive, home visiting curriculum)
Number of subjects: 102
Study 31050026 — intervention group
Group type: COMPARATOR
Intervention: Control home visiting curriculum
Number of subjects: 102
Study 29505146 — intervention group
Group type: EXPERIMENTAL
Intervention: Air displacement plethysmography (ADP) measurements at 37.5±0.7 weeks (Time 1) and 41.0±0.7 weeks (Time 2) postmenstrual age
Number of subjects: 22
Study 27410176 — intervention group
Group type: EXPERIMENTAL
Intervention: Testicular warming in a 43 °C water bath for 10 consecutive days
Number of subjects: 20
Study 27410176 — intervention group
Group type: EXPERIMENTAL
Intervention: Testicular warming in a 43 °C water bath once every 3 days
Number of subjects: 20
Study 24756462 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of ibandronic acid (T)
Number of subjects: 153
Study 24756462 — intervention group
Group type: COMPARATOR
Intervention: Bonviva(®) (R) - first dosing
Number of subjects: 153
Study 24756462 — intervention group
Group type: COMPARATOR
Intervention: Bonviva(®) (R) - second dosing
Number of subjects: 153
Study 22059618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention based on the Theory of Planned Behavior (TPB)
Number of subjects: 45
Study 22059618 — intervention group
Group type: COMPARATOR
Intervention: General control condition
Number of subjects: 45
Study 22059618 — intervention group
Group type: COMPARATOR
Intervention: Mere measurement control condition
Number of subjects: 45